Pharmacological inhibition of SRC-3 with gambogic acid reduced tumor growth of diffuse large cell b cell lymphoma (DLBCL) models in vitro and in vivo through histone deacetylation and downregulation of multiple oncoproteins such as Bcl-2, cyclin D3, Bcl-6, and c-Myc [12]. Here, CCND3 is linked to diffuse large B-cell lymphoma.